Profil
Jeffrey Hager was the founder of IDEAYA Biosciences, Inc. founded in 2015, where he held the title of Chief Technology Officer & Senior Vice President.
He held former positions as Associate Director-Biology at Apoptos, Inc. from 2008 to 2009, Director at Aragon Pharmaceuticals, Inc. in 2013 to 2014, Head-Cancer Pharmacology at Kalypsys, Inc. from 2004 to 2007, and Vice President-Biology at Seragon Pharmaceuticals, Inc. from 2014 to 2015.
Dr. Hager received his undergraduate degree from Connecticut College and Princeton University and his doctorate from the University of California, Berkeley.
Anciens postes connus de Jeffrey Hager
| Sociétés | Poste | Fin |
|---|---|---|
Seragon Pharmaceuticals, Inc.
 Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/02/2015 |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/04/2014 |
Apoptos, Inc.
 Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Corporate Officer/Principal | 01/04/2009 |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Corporate Officer/Principal | 01/11/2007 |
| IDEAYA BIOSCIENCES, INC. | Fondateur | - |
Formation de Jeffrey Hager
| University of California, Berkeley | Doctorate Degree |
| Princeton University | Undergraduate Degree |
| Connecticut College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IDEAYA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Seragon Pharmaceuticals, Inc.
Seragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA. | Health Technology |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Apoptos, Inc.
Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Health Technology |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
